TN2019000112A1 - Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma - Google Patents
Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucomaInfo
- Publication number
- TN2019000112A1 TN2019000112A1 TNP/2019/000112A TN2019000112A TN2019000112A1 TN 2019000112 A1 TN2019000112 A1 TN 2019000112A1 TN 2019000112 A TN2019000112 A TN 2019000112A TN 2019000112 A1 TN2019000112 A1 TN 2019000112A1
- Authority
- TN
- Tunisia
- Prior art keywords
- citicoline
- glaucoma
- ophthalmic formulation
- liposome
- treatment
- Prior art date
Links
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 title abstract 3
- 229960001284 citicoline Drugs 0.000 title abstract 3
- 239000002502 liposome Substances 0.000 title abstract 3
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000003733 optic disk Anatomy 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000103956A IT201600103956A1 (it) | 2016-10-17 | 2016-10-17 | Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma |
| PCT/IB2017/056400 WO2018073720A1 (en) | 2016-10-17 | 2017-10-16 | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2019000112A1 true TN2019000112A1 (en) | 2020-10-05 |
Family
ID=58010202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2019/000112A TN2019000112A1 (en) | 2016-10-17 | 2017-10-16 | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10576039B2 (https=) |
| EP (1) | EP3525758B1 (https=) |
| JP (1) | JP7042262B2 (https=) |
| EA (1) | EA201990752A1 (https=) |
| ES (1) | ES2987910T3 (https=) |
| IT (1) | IT201600103956A1 (https=) |
| MX (1) | MX388927B (https=) |
| TN (1) | TN2019000112A1 (https=) |
| WO (1) | WO2018073720A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3054066T3 (en) | 2017-06-09 | 2026-01-29 | Omnivision Gmbh | Composition for the treatment of dry eye |
| IT201800005309A1 (it) * | 2018-05-11 | 2019-11-11 | Composizione ad attivita’ antimicrobica | |
| CN110559261A (zh) * | 2018-06-06 | 2019-12-13 | 常州药物研究所有限公司 | 含有纳米交联透明质酸的脂质体微乳及其制备方法和应用 |
| CN111840220B (zh) * | 2020-08-19 | 2022-09-30 | 开封康诺药业有限公司 | 一种胞磷胆碱钠注射液及其制备方法 |
| MX2023013266A (es) * | 2021-05-10 | 2023-12-15 | Omikron Italia S R L | Solucion oral basada en citicolina y nicotinamida para usar en el tratamiento del glaucoma. |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114577A1 (en) * | 1983-01-21 | 1984-08-01 | MAGIS FARMACEUTICI S.p.A. | New pharmaceutical composition |
| EP1334718A4 (en) * | 2000-10-26 | 2007-07-18 | Senju Pharma Co | DRUG COMPOSITION CONTAINING DIPEPTIDYL ALDEHYDE COMPOUND |
| CN102316852A (zh) * | 2009-02-11 | 2012-01-11 | 丽卡实验有限公司 | 脂质胞二磷胆碱注射液 |
| IT1398378B1 (it) * | 2010-02-22 | 2013-02-22 | Omikron Italia S R L | Citicolina per il trattamento del glaucoma e dell'ipertensione oculare. |
| FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US10272040B2 (en) * | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
| CN102078299B (zh) * | 2011-01-04 | 2012-09-26 | 海南美大制药有限公司 | 胞磷胆碱钠脂质体固体制剂 |
-
2016
- 2016-10-17 IT IT102016000103956A patent/IT201600103956A1/it unknown
-
2017
- 2017-10-16 MX MX2019004463A patent/MX388927B/es unknown
- 2017-10-16 EP EP17811373.4A patent/EP3525758B1/en active Active
- 2017-10-16 US US16/342,261 patent/US10576039B2/en active Active
- 2017-10-16 WO PCT/IB2017/056400 patent/WO2018073720A1/en not_active Ceased
- 2017-10-16 ES ES17811373T patent/ES2987910T3/es active Active
- 2017-10-16 TN TNP/2019/000112A patent/TN2019000112A1/en unknown
- 2017-10-16 JP JP2019520647A patent/JP7042262B2/ja active Active
- 2017-10-16 EA EA201990752A patent/EA201990752A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019530729A (ja) | 2019-10-24 |
| IT201600103956A1 (it) | 2018-04-17 |
| MX2019004463A (es) | 2019-09-11 |
| EP3525758B1 (en) | 2024-05-22 |
| JP7042262B2 (ja) | 2022-03-25 |
| MX388927B (es) | 2025-03-20 |
| US20190321292A1 (en) | 2019-10-24 |
| EP3525758C0 (en) | 2024-05-22 |
| EP3525758A1 (en) | 2019-08-21 |
| WO2018073720A1 (en) | 2018-04-26 |
| EA201990752A1 (ru) | 2019-09-30 |
| US10576039B2 (en) | 2020-03-03 |
| ES2987910T3 (es) | 2024-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2019000112A1 (en) | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma | |
| PH12020551766A1 (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| IL273531A (en) | Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases | |
| EP4248971A3 (en) | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| MY199237A (en) | Methods of treating ocular conditions | |
| MX2019008621A (es) | Peptidos terapeuticos y neuroprotectores. | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| PT3413868T (pt) | Composição oftálmica para utilização no tratamento de distúrbios oculares relacionados com alterações da superfície córneo-conjuntival | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| MX394915B (es) | Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3 | |
| MX2016006256A (es) | Tratamiento de glaucoma usando laquinimod. | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras | |
| CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
| IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases | |
| ZA202100656B (en) | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases | |
| BR112017007102A2 (pt) | uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica | |
| TW201613596A (en) | Ophthalmic suspension preparation |